Cresco Labs Inc.
CRLBFOTCHealthcare● Active
$0.94
$-0.01(-1.44%)
Market Cap$331572857
P/E Ratio—
52W High$2.3
52W Low$0.426
Cresco Labs Inc. (CRLBF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRLBF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.04
Est. -$0.03 · -33.3%
Revenue
$0.15B
Est. $0.15B · +1.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CRLBF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.02 | — | — | — | $0.17B | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.03 | -$0.04 | -33.3% | $0.15B | $0.15B | +1.9% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.01 | -$0.24 | -1503.2% | $0.16B | $0.16B | +0.5% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.03 | -$0.05 | -66.7% | $0.17B | $0.16B | +0.5% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.04 | -$0.05 | -25.0% | $0.16B | $0.17B | -2.9% |
| ▼ Q2 FY2025 | May 30, 2025 | -$0.03 | -$0.04 | -33.3% | $0.17B | $0.17B | -2.9% |
| — Q1 FY2025 | Mar 12, 2025 | -$0.01 | -$0.01 | +0.0% | $0.18B | $0.17B | +1.5% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.00 | -$0.02 | -474.7% | $0.18B | $0.17B | +3.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.04
EPS Est.
-$0.03
EPS Surpr.
-33.3%
Revenue
$0.15B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.24
EPS Est.
-$0.01
EPS Surpr.
-1503.2%
Revenue
$0.16B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.05
EPS Est.
-$0.03
EPS Surpr.
-66.7%
Revenue
$0.17B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.05
EPS Est.
-$0.04
EPS Surpr.
-25.0%
Revenue
$0.16B
Q2 FY2025
May 30, 2025Miss
EPS Actual
-$0.04
EPS Est.
-$0.03
EPS Surpr.
-33.3%
Revenue
$0.17B
Q1 FY2025
Mar 12, 2025
EPS Actual
-$0.01
EPS Est.
-$0.01
EPS Surpr.
+0.0%
Revenue
$0.18B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.00
EPS Surpr.
-474.7%
Revenue
$0.18B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q4 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -33.3% | $1.10 | $1.04 | -5.45% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -1503.2% | $0.98 | $0.93 | -4.82% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -66.7% | $1.07 | $1.08 | +0.93% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -25.0% | $0.69 | $0.68 | -1.41% |
| ▼ Q2 FY2025 | May 30, 2025 | -33.3% | $0.68 | $0.60 | -11.29% |
| ▲ Q1 FY2025 | Mar 12, 2025 | +0.0% | $0.74 | $0.75 | +0.54% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -474.7% | $1.28 | $1.24 | -3.13% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -1500.0% | $1.45 | $1.62 | +11.72% |
Q2 FY2026-5.45%
Report Date
May 8, 2026
EPS Beat/Miss
-33.3%
Price Before
$1.10
Price After
$1.04
Q1 FY2026-4.82%
Report Date
Mar 5, 2026
EPS Beat/Miss
-1503.2%
Price Before
$0.98
Price After
$0.93
Q4 FY2025+0.93%
Report Date
Nov 5, 2025
EPS Beat/Miss
-66.7%
Price Before
$1.07
Price After
$1.08
Q3 FY2025-1.41%
Report Date
Aug 7, 2025
EPS Beat/Miss
-25.0%
Price Before
$0.69
Price After
$0.68
Q2 FY2025-11.29%
Report Date
May 30, 2025
EPS Beat/Miss
-33.3%
Price Before
$0.68
Price After
$0.60
Q1 FY2025+0.54%
Report Date
Mar 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.74
Price After
$0.75
Q4 FY2024-3.13%
Report Date
Nov 8, 2024
EPS Beat/Miss
-474.7%
Price Before
$1.28
Price After
$1.24
Q3 FY2024+11.72%
Report Date
Aug 8, 2024
EPS Beat/Miss
-1500.0%
Price Before
$1.45
Price After
$1.62
Avg Beat Reaction+0.54%
Avg Miss Reaction-1.92%
Beat Rate1 / 8 quarters
Largest Move+11.72% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRLBF ends December
Cresco Labs Inc. (CRLBF) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.04 — missing the analyst consensus of $-0.03 by -33.3%. The next CRLBF earnings date is expected around September 1, 2026.
Each quarter, investors track CRLBF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRLBF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRLBF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRLBF earnings · 5 questionsCresco Labs Inc.'s next earnings report is expected around September 1, 2026. CRLBF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRLBF historically reports after market close (AMC).
CRLBF earnings datewhen is CRLBF earningsCRLBF next earnings datewhen does CRLBF report earningsCRLBF earnings calendar
▸ Source: FMP · Cresco Labs Inc. SEC filings · US GAAP · Cresco Labs Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026